Phase 2 and 3 trials in Alzheimer’s drug development by region 2023

Published by
Matej Mikulic,
Jun 6, 2023
As of January 1, 2023, 49 percent of phase II clinical trials in the Alzheimer’s disease drug development pipeline were located in North America (U.S. & Canada) only, while the percentage was at 26 percent for phase III clinical trials targeting this disease.

Share of phase II and III trials targeting the Alzheimer’s disease as of 2023, by location

Loading statistic...

© Statista 2023
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

March 2023

Region

Worldwide

Survey time period

as of January 1, 2023

Supplementary notes

Missing percentage points to 100 percent are probably due to rounding.

Citation formats
Statista Accounts: Access All Statistics. Starting from $1,788 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$149 USD / Month *
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Other statistics that may interest you

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Statistics on

About the industry

10

About the region

10

Selected statistics

6

Other regions

10

Related statistics

10

Further related statistics

10

Further Content: You might find this interesting as well

Statistics

Topics

Dementia and Alzheimer's disease in CanadaDeath in CanadaDementia and Alzheimer's disease in the United StatesGeriatric health in the U.S.Diseases in Canada
Statista Accounts: Access All Statistics. Starting from $1,788 USD / Year
Learn more about how Statista can support your business.
Menu